clinical trial · NCT06553768
Evaluation of Maralixibat in Pruritus Associated With General Cholestatic Liver Disease (EXPAND)
Cholestatic Liver Disease (Except ALGS, PFIC, PBC and PSC)MaralixibatPlacebo
brief summary
The purpose of this study is to determine whether the investigational treatment (maralixibat) is safe and effective in pediatric and adult participants who have cholestatic liver disease with pruritus that has been refractory to other therapies, and who have no other treatment options.
started
Oct 14, 2024
primary completion
Oct 1, 2026
completion
Feb 1, 2027
last updated
Mar 30, 2026
detailed description
This study will be conducted in multiple sites in North America, Europe, Middle East and South America.
official title
Randomized Double-Blind Placebo-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Maralixibat in the Treatment of Participants With Cholestatic Pruritus
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol